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Abstract
Purpose Primary ciliary dyskinesia (PCD) is a rare disorder of the mucociliary clearance leading to recurrent upper and lower 
respiratory tract infections. PCD is difficult to clinically distinguish from other entities leading to recurrent oto-sino-pulmonary 
infections, including primary immunodeficiency (PID). Nasal nitric oxide (nNO) is a sensitive and specific diagnostic test for 
PCD, but it has not been thoroughly examined in PID. Past publications have suggested an overlap in nNO levels among subjects 
with PCD and PID. We sought to determine if nNO measurements among patients diagnosed with PID would fall significantly 
above the established PCD diagnostic cutoff value of 77 nL/min.
Methods Children > 5 years old and adults with definitive PID or PCD diagnoses were recruited from outpatient subspecialty 
clinics. Participants underwent nNO testing by standardized protocol using a chemiluminescence analyzer and completed a 
questionnaire concerning their chronic oto-sino-pulmonary symptoms, including key clinical criteria specific to diagnosed PCD 
(neonatal respiratory distress at term birth, year-round cough or nasal congestion starting before 6 months of age, any organ 
laterality defect).
Results Participants included 32 patients with PID, 27 patients with PCD, and 19 healthy controls. Median nNO was 228.9.1 nL/
min in the PID group, 19.7 nL/min in the PCD group, and 269.4 in the healthy controls (p < 0.0001). Subjects with PCD were 
significantly more likely to report key clinical criteria specific to PCD, but approximately 25% of PID subjects also reported at 
least 1 of these key clinical criteria (mainly year-round cough or nasal congestion).
Conclusions While key clinical criteria associated with PCD often overlap with the symptoms reported in PID, nNO measure-
ment by chemiluminescence technology allows for effective discrimination between PID and PCD.
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Introduction
Primary ciliary dyskinesia (PCD) is a rare, genetic disease char-
acterized by abnormal motile ciliary structure, function, and
biogenesis [1]. The resulting impairment of mucociliary clear-
ance from the lungs, paranasal sinuses, and middle ear leads to
chronic respiratory symptoms from the early postnatal period,
with recurrent oto-sino-pulmonary infections and significant
pulmonary morbidity over time [1, 2]. Recognizing PCD is
difficult, as the symptoms seen in PCD often overlap with those
in other chronic respiratory diseases, including cystic fibrosis,
asthma, recurrent viral infections, and primary immunodefi-
ciency (PID). Through deep phenotyping of PCD populations,
researchers have discovered four key clinical features that are
sensitive and specific for PCD diagnosis, including (1) neonatal
respiratory distress requiring at least 24 h of supplemental ox-
ygen or positive pressure support, despite term birth, (2) year-
round, productive (often wet) cough starting before 6 months of
age, (3) year-round, non-seasonal nasal congestion starting be-
fore 6 months of age, and (4) any organ laterality defect (in-
cluding situs inversus totalis or situs ambiguus) [3].
Despite improved clinical phenotyping, there is still no single
diagnostic test that detects all cases of PCD. The Bgold standard^
for PCD diagnosis has traditionally been nasal or endobronchial
biopsy for ciliary ultrastructural analysis by transmission electron
microscopy (TEM), but this is estimated to capture only 70% of
affected individuals [4], as forms of PCD exist with normal TEM
ultrastructure. More than 40 different genes are known to cause
PCD. Although new genes are being discovered at an accelerat-
ed pace through whole exome sequencing, genetic testing iden-
tifies only 70% of PCD patients [5]. High-speed video micros-
copy (HSVM) is another PCD diagnostic tool, but this too fails
to detect all patients with PCD.Moreover, each of these tests can
give non-diagnostic results, while TEM and HSVM require spe-
cialized expertise to perform correctly.
For unclear reasons, nasal nitric oxide (nNO) levels are
diminished in PCD, which led to nasal measurement of this
exhaled gas as a screening test for PCD [6–8]. Past publica-
tions have validated nNO measurement as 98% sensitive
and > 99% specific for PCD, when using a diagnostic cutoff
of 77 nL/min [9]. Additionally, nNO testing is rapid, non-
invasive, inexpensive for patients, easy to perform, and results
are immediately available. As a result, recent clinical practice
guidelines suggest nNO measurement, performed by a stan-
dard operating protocol, with chemiluminescence technology,
as a first-line diagnostic test for PCD [2, 10]. However, nNO
measurement has not been extensively evaluated in diseases
that present with symptoms similar to PCD, such as those seen
in certain PIDs. PIDs are inborn errors of immunity, some of
which compromise host defenses in the respiratory tract.
Consequently, patients with these PIDs can phenocopy some
aspects of patients with PCD and past publications have sug-
gested an overlap in nNO levels among subjects with PCD
and PID [11, 12]. We sought to prospectively examine the
ability of nNO measurement, using an established and vali-
dated diagnostic methodology in accordance with clinical
guidelines [10, 13], to discriminate between the clinically sim-
ilar entities of PCD and a well-phenotyped group of patients
with PID. We hypothesized that nNO levels in patients with
PIDwould fall above the PCD diagnostic cutoff of 77 nL/min,
particularly when repeated on multiple occasions.
Methods
Study Population
Participants were recruited from adult and pediatric
Immunodeficiency and Pulmonology clinics at the McGill
University Health Center (MUHC). Recruitment was limited to
subjects ≥ 5 years old, who were able to cooperate with the
technique required to obtain reliable nNO values. Recruited par-
ticipants had a clear basis (either clinical or genetic) for their
diagnosis of PID as well as histories of chronic ear, sinus, or
pulmonary disease in their medical records (Table 1) [14].
Diagnoses were reviewed with a board-certified immunologist
(RA), when necessary. Subjects were clinically stable and free of
upper or lower respiratory tract infections in the 2 weeks prior to
nNO measurement. The participants were in clinic for a mini-
mum of 2 h prior to nNO testing. During this period, there was
no exercise, smoking, nasal instrumentation, nasal medication
administration, nor known food or drink consumption.
Nasal nitric oxide values and clinical research data from all
definitively diagnosed PCD subjects, followed in the PCD
clinics of the MUHC, were included in this study. All PCD
subjects were diagnosed through either a classic, disease-
causing ultrastructural defect on TEMor two pathogenic variants
in one of the known PCD genes. High-speed videomicroscopy
analysis was not performed on this population.
A standardized clinical questionnaire was administered to
all PID subjects on the day of enrollment (see supplemental
materials). In addition, medical records were reviewed for
pertinent clinical information. Spirometry was also performed
on the day of study enrollment. If spirometry was not feasible
at the study visit, clinical spirometry testing within 6 months
was abstracted from themedical record, if available. The study
design (14-019-PED) was reviewed by the Research Ethics
Board of the MUHC. Informed consent was obtained from
participants included in the study.
Nasal Nitric Oxide Measurements
Nasal nitric oxide measurements were performed using a
CLD88 chemiluminescence analyzer (EcoPhysics, AG,
Duernten, Switzerland) per the standard operating protocol
of the Genetic Diseases of Mucociliary Clearance
Consortium (GDMCC) and the PCD Foundation Clinical and
Research Center Network [13]. To perform this test, a plastic
catheter with a surrounding soft nasal sponge was placed into
one nare to ensure an airtight seal. Participants performed
maneuvers to close their velum, which prevents dilution of
nasal gas (containing much higher nitric oxide levels) with
gas from the lower airways. To accomplish this, participants
inhale to total lung capacity and exhale into a resistor or a
child’s party favor, which is partially occluded at one end,
for at least 10 s. This technique produces an initial washout
phase followed by a nitric oxide concentration plateau phase,
which signifies steady state nitric oxide sampling from the
nasal cavity. The same procedure is repeated in the contralat-
eral nare. The mean of two separate plateau measurements (at
least 3-s duration each, with < 5% variation from the horizon-
tal axis) were calculated for each nare, followed by a calcula-
tion of the mean for both nares together to yield an average test
result in parts per billion. Final values are expressed in
nanoliters per minute, which are a product of the concentration
(in parts per billion) and the flow rate of transnasal airflow in
the sampling catheter (in liters/min) yielding nasal nitric oxide
production values (in nL/min). A standard transnasal airflow
sampling rate of 0.33 l per minute was verified before and
after each subject tested. Ambient nitric oxide levels were
recorded and were consistently less than 50 parts per billion.
Measurements were performed by one of three operators, who
were extensively trained and experienced with the standard-
ized nNO measurement protocol. All nNO raw data curves
were reviewed and verified by the lead device operator (AJS).
Statistics
All statistical analyses were performed using Prism GraphPad
(Version 7.0c, 2007, California). Demographic data is report-
ed as the median with interquartile range. Differences in clin-
ical symptoms and demographic features were computed
using Fisher’s exact tests at a 5% level of significance. Nasal
nitric oxide values between subjects with PCD, and PID and
healthy controls were compared using a Kruskal-Wallis test,
given the non-parametric data distribution. Post-hoc pairwise
comparisons were performed by Mann-Whitney U tests.
Results
Demographic data for the PCD and PID subjects are shown in
Table 1. Clinical characteristics for both groups are described
in Table 2. Among the 32 participants with PID, diagnoses
included the following: polysaccharide antibody deficiency
(n = 2), common variable immunodeficiency (n = 14),
hypogammaglobulinemia (n = 8); X-linked agammaglobulin-
emia (n = 2), combined immunodeficiency (n = 2), X-linked
neutropenia (n = 1), complement deficiency (n = 1), autoso-
mal recessive RAG1 deficiency (n = 1), and autosomal reces-
sive STAT1 deficiency (n = 1).
Subjects with PCDwere significantly more likely to have key
clinical features of PCD, including a history of neonatal respira-
tory distress, daily year-roundwet cough before 6months of age,
daily year-round nasal congestion before 6 months of age, or
Table 1 Subject characteristics
PCD (n = 27) PID (n = 32)
Median age in years (IQR) 18.6 (9.7–38.6) 16.5 (9.8–45.3)
Male sex (%) 12 (44) 17 (53)
White race (%) 18 (67) 26 (81)
Median FEV1% predicted (IQR) 81 (59–91) 94.1 (87–101)*
Median FVC % predicted (IQR) 92 (80–99) 97 (87–106)
Median FEV1/FVC % predicted (IQR) 88 (83–89) 87 (83–90)
Treatment nasal CS (%) 17 (63) 17 (53)
Treatment nasal saline lavage (%) 13 (48) 0 (0)*
Previous FESS (%) 12 (44) 4 (13)*
Past nasal polyps (%) 6 (22) 0*
Prophylactic oral antibiotics (%)† 8 (30) 12 (38)
Prophylactic inhaled antibiotics (%)‡ 2 (7) 0
IVIG replacement (%) 0 23 (72)*
Current smoker (%) 0 6 (19)*
Smoker in the home (%) 0 7 (22)*
PID primary immunodeficiency disease, PCD primary ciliary dyskinesia, FEV1 forced expiratory volume in 1 s,
FVC forced vital capacity, CS corticosteroid, IVIG intravenous immunoglobulin
*Statistically significant values using Fisher Exact Test
†Azithromycin, moxifloxacin, ciprofloxacin, TMP-SMX, amoxicillin
‡ Inhaled tobramycin
organ laterality defects than subjects with PID. Sensitivities and
specificities were calculated for each symptom individually
(Table 2). Twenty-five percent of PID patients had ≥ 1 key clin-
ical feature of PCD, while 16% had ≥ 2 key PCD clinical fea-
tures on history. Sensitivity and specificity for the combination of
daily year-round wet cough and daily year-round nasal conges-
tion starting before 6 months of age was 88.9% and 90.6%,
respectively, for the diagnosis of PCD in this study. Sensitivity
and specificity for the combination of neonatal respiratory dis-
tress and organ laterality defects was 98.1% and 100%, respec-
tively (Table 2). Sinusitis verified on CT scan was not signifi-
cantly more prevalent in the PCD group (57%) versus the PID
group (42%, p = 0.7) and there was no significant difference in
historically reported sinusitis episodes between groups. Despite
similarities in median age and sex distribution between groups,
14/16 (87%) of PCD patients had bronchiectasis on CT scan
compared to 8/21 (38%) PID patients who underwent CT imag-
ing (p < 0.003) before study enrollment.
Pulmonary function was assessed using Global Lung
Initiative predictive equations [15]. The FEV1 values were
significantly different between PCD and PID groups, with a
median FEV1 of 81% and 94% predicted, respectively (p =
0.004). The FVC and FEV1/FVC values did not vary signif-
icantly between disease groups. Some therapeutic regimens
also significantly differed between the PCD and PID groups.
Forty-eight percent of PCD subjects versus 0% of PID sub-
jects were on daily nasal saline lavage (p < 0.0001). Subjects
with PCD were more likely to have been diagnosed with past
nasal polyps (p = 0.07) and to have undergone past functional
endoscopic sinus surgery (FESS) (p = 0.008). Other treatment
modalities were similar between groups. For example, 30% of
PCD subjects versus 38% of PID subjects received prophy-
lactic oral antibiotics (p = 0.59) and 63% of PCD subjects
versus 53% of PID subjects (p = 0.63) were on daily nasal
corticosteroids (Table 1).
Initial nNO testing was performed in 32 PID and 27 PCD
subjects, while repeat nNO testing was performed in 9 PID
and 17 PCD cases. In addition, 19 healthy controls underwent
nNO testing. Median initial nNO values in the PCD, PID, and
healthy control groups were 19.7, 228.9, and 269.4 nL/min,
respectively (p < 0.0001) (Fig. 1). Two PID subjects had initial
nNO levels below the diagnostic cutoff of 77 nL/min, but both
increased above 77 nL/min on repeat testing (Fig. 2).
However, one PID subject with normal nNO values on repeat
testing subsequently redeveloped nNO values below 77 nL/
min. Of the PCD subjects, all but one had initial nNO levels
below the diagnostic cutoff of 77 nL/min. On repeat nNO
testing, only 1 PCD participant had nNO levels rise slightly
above 77 nL/min (Fig. 3). Thus, the sensitivity and specificity
of repeat nNO measurements in distinguishing subjects with
PCD from subjects with PID in this population was 97% and
91%, respectively, using the cutoff of 77 nL/min.
Discussion
PCD and certain PIDs can both manifest with recurrent respi-
ratory tract infections. Accurately distinguishing these two
Table 2 Clinical features of patients with PCD and PID
PCD PID p value Sens Spec
(n = 27) (n = 32) (%) (%)
n (%) n (%)
4 key clinical features of PCD [3]
Neonatal respiratory distress despite term birth† 19 (70) 1 (3) p < 0.0001* 70.4 96.9
Daily, year-round wet cough starting before 6 months old 26 (96) 3 (9) p < 0.0001* 96.2 90.6
Daily, year-round nasal congestion starting before 6 months old 25 (93) 3 (9) p < 0.0001* 92.6 90.6
Any organ laterality defect 18 (67) 1 (3) p < 0.0001* 66.6 96.1
Daily, year-round wet cough AND daily, year-round nasal congestion 24 3 p < 0.0001* 88.9 90.6
Neonatal respiratory distress AND any organ laterality defect 13 0 p < 0.0001* 48.1 100
1 key PCD clinical feature 27 (100) 8 (25) p < 0.0001*
≥ 2 key PCD clinical features 27 (100) 5 (16) p < 0.0001*
Other clinical features in adults with PCD [40]
Bronchiectasis on CT chest 14 (88) 8 (38) p = 0.003*
(n = 16) (n = 21)
Pansinusitis on CT sinus 8 (57) 5 (42) p = 0.7
(n = 14) (n = 12)
PCD primary ciliary dyskinesia, PID primary immunodeficiency, sens sensitivity, spec specificity, CT computed tomography
†Neonatal respiratory distress defined as need for supplemental oxygen or positive pressure support for more than 24 h, despite term birth
*Statistically significant value using Fisher’s exact test
entities has important clinical implications. This study con-
firms that nNO testing accurately discriminates between
PCD and PID in most cases. Most importantly, repeat nNO
testing in PID patients with initially low nNO values was
normalized on subsequent measurements (above 77 nL/min)
in all subjects, while nNO remains persistently low in most
subjects with PCD. As nNO values can be transiently de-
creased by nasal bleeding, acute viral respiratory infection
and other disease states, repeat nNO testing is vital in patients
with key PCD clinical symptoms [17, 18]. Only a few condi-
tions, including allergic rhinitis or acute bacterial sinusitis [19,
20], have been reported to artificially raise nNO values.
However, these conditions have also been reported to decrease
nNO values in certain settings [21, 22]. PID subjects with
transiently low nNO values in this study likely had occult viral
infections or other secondary causes of their low nNO levels.
Normalization of nNO values over time argues strongly
against PCD and should direct clinicians to pursue further
investigations for PID and/or other respiratory diseases [23].
In addition to nNO values, clinical symptom history by
standardized questionnaire appears to provide good diagnostic
discrimination between PCD and PID. For each of the four
key PCD clinical criteria, subjects with PCD were significant-
ly more likely to possess the symptom than subjects with PID.
Sensitivities and specificities in PCD were highest for daily
year-round wet cough and daily year-round nasal congestion
beginning before 6 months of age. Although the presence of
an organ laterality defect had a sensitivity of only 67%, the
specificity was quite high, suggesting that a laterality defect,
when present, should point the clinician toward the diagnosis
of primary ciliary dyskinesia. A substantial percentage of PID
subjects (25%) displayed one or more of these key clinical
criteria, emphasizing the significant overlap in symptoms be-
tween these two entities, and the value of a rapid, non-inva-
sive, and inexpensive test (like nNO measurement) to delin-
eate between them. Clinical immunologists may benefit from
this quick diagnostic test when key PCD clinical features are
present, as it may direct toward nNO testing (a test not always
considered in the evaluation of such patients) and avoid ex-
tensive and costly immunological testing.
Even though the clinical features of PCD and PID closely
overlap, nNO testing in PID has not been widely investigated
to distinguish between these diseases. Early publications on
nNO values in PID included limited numbers of subjects, yet
clinical information on the type of immune dysfunction are
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Fig. 1 Initial nNO in primary immunodeficiency, PCD, and healthy
controls were compared using a Kruskal-Wallis test with post-hoc
pairwise Mann-Whitney U tests. Horizontal lines represent the group
median. Dashed line represents the PCD diagnostic cutoff of 77 nL/
min. ****p < 0.0001. Only two PCD subjects (both with pathogenic var-
iants in RSPH1) had initial or repeat nNO values above the PCD diag-
nostic cutoff of 77 nL/min (solid black horizontal line). This is consistent
with previous observations that pathogenic variants in RSPH1 can some-
times result in nNO measurements above the diagnostic cutoff [16]. Two
PID subjects initially had nNOmeasurements below the diagnostic cutoff
of 77 nL/min. Both of these subjects eventually had nNO measurements
that rose above 77 nL/min, although one subject with RAG1 immunode-
ficiency had repeat nNO values fall below this cutoff
small [11, 24]. Boon and colleagues explored nNO testing in
48 subjects with humoral PID, yet they did not collect detailed
information on chronic respiratory symptoms and they en-
rolled many subjects with more debatable forms of immune
dysfunction, including isolated IgA deficiency and IgG sub-
class deficiency [12]—abnormalities that are also reported in
subjects without symptoms of immunodeficiency. To our
knowledge, our study is the first to examine nNO testing in
a well-phenotyped population with clinically significant forms
of PID. Furthermore, while past studies report nNO values in
humoral PID [12, 24], we report nNO values in a broader
array of PID, including humoral, innate, and combined immu-
nodeficiencies. Although our numbers are small, these PID
patients display chronic respiratory symptoms overlapping
with PCD, emphasizing the real-world similarities between
these rare diseases.
This is also the first report on diagnostic accuracy of nNO
testing in PID patients since the current PCD diagnostic cutoff of
77 nL/min was rigorously validated through multi-center study
[13]. Past studies of nNO in PID used different nNO diagnostic
cutoff values (62.5 and 90 nL/min) and measurement protocols
(breath hold or exhalation against resistance), which may have
affected diagnostic accuracy conclusions [11, 12]. This study
employs the standard operating protocol used by the Genetic
Diseases of Mucociliary Clearance Consortium and the PCD
Foundation Clinical and Research Center Network: these net-
works are comprised of 17 accredited PCD specialty centers
across North America, and this identical nNO protocol was used
to establish the current PCD diagnostic nNO cutoff of 77 nL/
min [13]. This protocol also falls within the recommendations of
the American Thoracic Society/European Respiratory Society
for nNO measurement [25].
One PID subject had several low nNO values (3/6 measure-
ments < 77 nL/min) during this study. This subject was inves-
tigated for PCD and had normal electron microscopy and a
panel of 21 PCD genes that did not reveal any pathogenic
variants, yet neither of these negative tests effectively rules
out PCD. Eventually, this subject was discovered to have ho-
mozygous, pathogenic variants in RAG1 on targeted genetic
analysis following abnormal V-ß repertoire testing. The vari-
able nNO values in this case may be due to the difficulty in
clearing nasal viral infections, known to decrease nNO values,
associated with combined immunodeficiency [26–29].
Alternatively, an oligogenic syndrome, consisting of RAG1 de-
ficiency with a PCD defect due to one of the newly discovered
genes not accounted for in the panel, is possible, especially as
the subject’s parents were consanguineous, thereby increasing
the risk of recessive diseases. Among the PCD subjects, two
patients had nNO measurements above the diagnostic cutoff of
77 nL/min. Both of these subjects carried two pathogenic var-
iants in RSPH1, resulting in a form of PCD affecting radial
spoke heads and sometimes producing nNO levels above
77 nL/min [16]. RSPH1 pathogenic variants are a relatively rare
cause of PCD, which affect only 2% of diagnosed individuals
and do not cause organ laterality defects [30]. In the future,
there may be more forms of genetically diagnosed PCD with
nNO levels above the accepted cutoff of 77 nL/min, but RSPH1
is the only currently known PCD gene that regularly results in
non-diagnostic nNO levels. This finding should be kept in mind
when clinically evaluating patients with a PCD phenotype, but
for which nNO and immunologic investigations are
unrevealing. With increased availability of commercial genetic
testing, it may be possible to run combined PID and PCD
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Fig. 3 One PCD subject with
RSPH1 and longitudinal
measurements mutation had one
of three values above the
diagnostic cutoff of 77 nL/min.





Approximately one-third of PID subjects (31%) had
nNO levels that were above 77 nL/min, yet still fell below
nNO values commonly seen in healthy subjects (generally
> 200 nL/min) [3]. For many of these PID subjects, repeat
nNO measurements were not available, so it is unclear
how these values might have progressed over time. Of
the subjects with intermediate nNO values, 4 of them
underwent repeat testing, and 3 of them had at least one
test greater than 200 nL/min. Intermediate nNO values
have been described in cystic fibrosis [31] and heterotaxy
syndrome [32] and therefore, may also be present among
patients with certain subtypes of PID. Multi-center, cross
sectional analysis of large numbers of PID patients, with
systematic PCD and immunologic evaluation, would be
necessary to uncover such nNO trends and clinical corre-
lations in various subtypes of PID. In our study, 55% of
PCD patients had at least partial, normal clinical immune
testing, yet only 34% of our PID cohort had clinical PCD
testing, reflecting the real-world clinical practice of indi-
vidual subspecialties. Although presumably rare, reports
of oligogenic syndromes, with co-occurrence of PCD and
humoral PID, are published on a few patients [33, 34].
Treatment with nasal saline lavage (p < 0.0001) or FESS
(p = 0.008) was significantly more common in subjects
with PCD versus those with PID. Nasal corticosteroid use
did not differ significantly between groups. Although some
small studies suggest that nNO increases post-FESS [22,
35, 36], others contradict this, and a meta-analysis did not
find convincing support for the notion that nNO is a useful
marker of clinical improvement post-FESS [37]. Similarly,
there is conflicting evidence from a handful of small stud-
ies about whether the use of nasal corticosteroids influ-
ences nNO levels [36–38].
This study does have certain limitations. Our sample
sizes are relatively small, although this is not surprising
given that PCD and PID are both rare diseases.
Additionally, approximately one-third of PID participants
underwent repeat nNO testing, so the ability to extrapolate
patterns from this longitudinal data is limited. At the time
of study, many PID participants were receiving immuno-
globulin replacement with control of their clinical symp-
toms but were asked to recall symptoms at the time of
their PID diagnosis, lending itself to potential recall bias.
However, this bias is reduced by our meticulous review of
past clinical symptoms in participants’ medical records.
Lastly, this is not a study of prospectively referred symp-
tomatic subjects with possible PID or PCD, so the diag-
nostic accuracy of nNO testing is possibly overestimated.
Nonetheless, a previous multi-site, prospective study of
nNO in children with chronic oto-sino-pulmonary disease
has confirmed the excellent diagnostic accuracy (sensitiv-
ity 98%; specificity > 99%) of nNO for PCD versus other
respiratory diseases [12].
Conclusions
This study confirms that nNO measurement discriminates be-
tween patients with primary ciliary dyskinesia and various
forms of primary immunodeficiency. This suggests that nNO
can be employed as an early, non-invasive, and relatively in-
expensive test in the investigation of pediatric and adult pa-
tients with chronic oto-sino-pulmonary symptoms and assist
in proper referral of patients to immunology versus
pulmonology subspecialists. Standardized operating protocols
and chemiluminescence analyzers are essential for accurate
nNO measurements.
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